US Patent

US7749532 — Once daily formulations of tetracyclines

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2027-12-19 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects once-daily formulations of tetracyclines, such as doxycycline, for treating various diseases including periodontal disease and acne.

USPTO Abstract

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

Drugs covered by this patent

Vibramycin (doxycycline) · Generic (originally Pfizer)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1063`	—	Vibramycin

Patent Metadata

Patent number: US7749532
Jurisdiction: US
Classification: Method of Use
Expires: 2027-12-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.